Skip to main content
SpringerLink
Log in

HIV protease inhibitors: an important advance

  • New Drugs and Therapeutic
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Saquinavir mesylate monograph. AHFS Drug Information 96. Current developments. Bethesda: American Society of Hospital Pharmacists, 1996: 47–54

    Google Scholar 

  2. Moyle G, Gazzard B. Current knowledge and future prospects for the use of HIV protease inhibitors. Drugs 1996 May; 51(5): 701–12

    Article  PubMed  CAS  Google Scholar 

  3. Indinavir sulfate. AHFS Drug Information 96. Current developments. Bethesda: American Society of Hospital Pharmacists, 1996: 24–28

    Google Scholar 

  4. Lea AP, Faulds D. Ritonavir. Drugs 1996 Oct; 52(4): 541–9

    Article  PubMed  CAS  Google Scholar 

  5. Noble S, Faulds D. Saquinavir: a review of its pharmacology and clinical potential in the management of HIV infection. Drugs 1996 Jul; 52(1): 93–112

    Article  PubMed  CAS  Google Scholar 

  6. New drugs for HIV infection. Med Lett 1996 Apr 12; 38(972): 35–7

  7. Merck Crixivan temporary distribution to begin filling scripts March 25 through independent pharmacy service; scale-up facilities to be ready in six months. The Pink Sheet, FDC Reports 1996 Mar 18: 4

    Google Scholar 

  8. Swift US approval for Abbott’s Norvir. Scrip 1996 Mar 8; (2109): 17

  9. Carpenter CJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996: Recommendations of an international panel. JAMA 1996 Jul 10; 276(2): 146–56

    Article  PubMed  CAS  Google Scholar 

  10. Merck’s Crixivan recommended for US approval. Scrip 1996 Mar 8; (2109): 18

  11. Vella S, Galluzzo C, Giannini G, et al. Saquinavir/zidovudine combination in patients with advanced HIV infection and no prior antiretroviral therapy: CD4+ lymphocyte/plasma RNA changes, and emergence of HIV strains with reduced phenotypic sensitivity. Antiviral Res 1996; 29: 91–3

    Article  PubMed  CAS  Google Scholar 

  12. Cameron DW, Heath-Chiozzi M, Kravcik S, et al. Prolongation of life and prevention of AIDS complications in advanced HIV immunodeficiency with ritonavir; update [abstract]. XI International Conference on AIDS; 1996 Jul 7; Vancouver

  13. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996; 334: 1011–7

    Article  PubMed  CAS  Google Scholar 

  14. Bleeding warnings for protease inhibitors. Scrip 1996 Jul 26; (2149): 17

  15. Norvir capsules and solution. Pharm J 1996 Sep 7; 257: 330

    Google Scholar 

  16. New data on protease inhibitors from Vancouver. Scrip 1996 Jul 23; (2148): 17

  17. Schapiro JM, Winters MA, Kozal MJ, et al. Saquinavir monotherapy trial: prolonged suppression of viral load and resistance mutations with higher dosage [abstract no. LB-5]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17–20; San Francisco, 8

  18. Lamivudine and stavudine: useful additions to the available nucleoside analogues. Drug Ther Perspect 1996 Oct 14; 8(8): 1–6

    Article  Google Scholar 

  19. Moore RD, Bartlett JG. Combination antiretroviral therapy in HIV infection: an economic perspective. PharmacoEconomics 1996 Aug;10(2): 109–13

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

HIV protease inhibitors: an important advance. Drugs Ther. Perspect 8, 1–6 (1996). https://doi.org/10.2165/00042310-199608100-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199608100-00001

Search

Navigation